The U.S. Food and Drug Administration on Wednesday approved Sanofi’s oral drug venglustat, the first treatment approved for the neurological symptoms of type 3 Gaucher disease, a rare genetic condition affecting the brain and nervous system. Sanofi will sell the drug, venglustat, under the brand name Infilbray. It is a once-daily oral medicine approved for adults and children who weigh at least 15 kilograms, about 33 pounds. Sanofi said the approval covers the neurological manifestations of the disease, which include problems with balance, coordination, speech, memory and thinking that can worsen over time. The FDA announced the decision on November 18, 2026.
How venglustat works
Type 3 Gaucher disease is a rare, inherited lysosomal storage disorder. Mutations in the GBA1 gene leave the body short of glucocerebrosidase, an enzyme that breaks down fatty substances called glycosphingolipids. Without enough of the enzyme, those substances build up in organs, tissues and the brain. In type 3 disease, the buildup in the central nervous system causes the neurological symptoms, while patients also face enlarged liver and spleen, anemia, low platelet counts and bone disease. Enzyme replacement therapy controls the effects outside the brain but cannot reach the brain itself. Venglustat is an oral glucosylceramide synthase inhibitor designed to cross the blood-brain barrier and reduce the buildup of glycosphingolipids in the body and the brain.
Type 3 Gaucher disease is the chronic neuronopathic form of the disease. Unlike type 1 Gaucher disease, which typically lacks central nervous system involvement, type 3 affects balance, coordination, speech, memory and thinking, and these symptoms can worsen over time.
What the venglustat trial showed
The approval rests on the phase 3 LEAP2MONO trial, which enrolled 43 patients aged 12 and older whose systemic disease had stabilized on enzyme replacement therapy. The patients had received enzyme replacement therapy for at least three years and had reached therapeutic goals for systemic disease. The patients were assigned at random to once-daily oral venglustat or intravenous imiglucerase every two weeks for 52 weeks, in a double-blind, double-dummy design. The trial measured change in ataxia on the modified Scale for Assessment and Rating of Ataxia and change in thinking on the Repeatable Battery for the Assessment of Neuropsychological Status. On a global test combining both measures, patients receiving venglustat improved compared with those receiving enzyme replacement therapy. Sanofi has not publicly reported effect sizes or confidence intervals for the individual measures.
Venglustat safety warnings
The label carries warnings for suicidal thoughts and behavior, clouding of the lens of the eye in younger patients, and harm to a developing fetus during pregnancy. The most common side effects reported in the study were diarrhea, spleen enlargement, nausea, depression, irritation or infection of the stomach and intestine, and vomiting. The FDA granted venglustat orphan drug designation and priority review, and the drug also carries fast track and breakthrough designations and a rare pediatric disease designation.
Acting FDA Commissioner Kyle Diamantas said, “For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms.” Pramod Mistry, director of the Yale Lysosomal Disease Center, said the approval “represents a major milestone for patients, families, and the global Type 3 Gaucher disease community.” Sanofi said the drug is still under regulatory review in Europe and Japan. The approval of venglustat gives Sanofi a third product for Gaucher disease, after enzyme replacement therapies including Cerezyme, whose label was expanded in January 2026 to include non-central nervous system manifestations of type 3 disease.
The trial was small, and its randomized phase lasted 52 weeks, a short window for a slowly progressive neurological disease. Whether the benefit persists is not yet known, and the open-label portion of the study is ongoing. Combined prevalence of types 2 and 3 Gaucher disease has been estimated at 0.02 to 0.08 per 100,000 people in Europe, and data on the neuronopathic forms are sparse. The approval was granted to Genzyme Corporation, a Sanofi company.

